AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1325880
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg/day for 3 weeks and then 20 mg/day for 4 weeks (n = 12)
Trial: 1325880
Drug: Doxazosin 1-8
RxNorm normalized name: doxazosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 1-8 mg/day
Trial: 1325880
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with doxazosin and enalapril
Trial: 30851536
Drug: Premature Infant
RxNorm normalized name: Premature infant formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Premature Infant Oral Motor Intervention (PIOMI) administered over 10 days.
Trial: 29214740
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone (400 μg) plus intravitreal antibiotics (0.2 mg vancomycin and 0.05 mg gentamicin)
Trial: 29214740
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus intravitreal antibiotics (0.2 mg vancomycin and 0.05 mg gentamicin)
Trial: 29214740
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone (400 μg) plus intravitreal antibiotics
Trial: 29214740
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus intravitreal antibiotics
Trial: 26768146
Drug: Drug Eluting
RxNorm normalized name: Drug eluting stent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug Eluting Balloon (DCB)
Trial: 27041697
Drug: Presurgical orthodontic
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Presurgical orthodontic treatment before secondary alveolar bone grafting (SABG)
Trial: 27041697
Drug: Conventional SABG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional SABG alone (without presurgical orthodontic treatment)
Trial: 20405117
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 80 ppm inhaled nitric oxide (iNO) and 100% oxygen (O(2))
Trial: 18315511
Drug: Scalp acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scalp acupuncture (scalp AP) sessions twice weekly for 9 months in group B, alongside language therapy (LT).
Trial: 18315511
Drug: Language therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Language therapy (LT) twice weekly for 9 months in both groups.
Trial: 12423324
Drug: Melatonin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (5 mg in the evening)
Trial: 10066203
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose rivastigmine (6-12 mg/day)
Trial: 10066203
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose rivastigmine (1-4 mg/day)
Trial: 1914054
Drug: Low-dose alfentanil
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose alfentanil (35.1 micrograms.kg‐1 then continuous infusion of 16.2 micrograms.kg‐1.hr‐1)
Trial: 1914054
Drug: Mid-dose alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mid-dose alfentanil (70.2 micrograms.kg‐1 then continuous infusion of 32.4 micrograms.kg‐1.hr‐1)
Trial: 1914054
Drug: High-dose alfentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alfentanil (105.3 micrograms.kg‐1 then continuous infusion of 48.6 micrograms.kg‐1.hr‐1)
Trial: 1914054
Drug: Fentanyl (8.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (8.3 micrograms.kg‐1 then continuous infusion of 1.6 micrograms.kg‐1.hr‐1)
Trial: 6307933
Drug: Pectin (36
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin (36 g/d for 3 weeks)
Trial: 29298102
Drug: Deer Bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deer Bone Extract (DBE) 550 mg/day for 12 weeks
Trial: 26792619
Drug: Aquatic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic therapy (pool exercises) starting 6 days after surgery
Trial: 26792619
Drug: Timing of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timing of aquatic therapy
Trial: 21841518
Drug: Combination paste
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination paste (morphine + methylprednisolone)
Trial: 21841518
Drug: Steroid paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid paste (methylprednisolone alone)
Trial: 21841518
Drug: Morphine paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine paste (morphine alone)
Trial: 12081672
Drug: Traditional injection
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional injection technique
Trial: 10638393
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine infusion (3.4-4.6 mg/kg/h for 24 hours in study I; 0.3-1.3 mg/kg/h for 6 days in study II)
Trial: 7022295
Drug: Low-dose CMF
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Trial: 7022295
Drug: Standard-dose CMF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Trial: 23211271
Drug: Joint reminiscence
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Joint reminiscence groups held weekly for 12 consecutive weeks, followed by monthly maintenance sessions for a further 7 months.
Trial: 15834098
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg oral moxifloxacin (two doses with a 12 hour interval)
Trial: 10566928
Drug: Laryngeal mask
RxNorm normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laryngeal mask airway (LMA) with cuff volumes ranging from 0 to 40 ml
Trial: 10566928
Drug: Cuffed oropharyngeal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cuffed oropharyngeal airway (COPA) with cuff volumes ranging from 0 to 60 ml
Trial: 27502803
Drug: Kinesio Taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio Taping (KT) in addition to neurodevelopmental therapy (NDT)
Trial: 27502803
Drug: Neuromuscular electrical
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neuromuscular electrical stimulation (NMES) in addition to neurodevelopmental therapy (NDT)
Trial: 24821594
Drug: Pyrazinamide MIC
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrazinamide MIC ≤ 50 mg/L
Trial: 24821594
Drug: Pyrazinamide MIC
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrazinamide MIC > 50 mg/L
Trial: 24821594
Drug: Standard combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard combination therapy (isoniazid, rifampicin, pyrazinamide, ethambutol)
Trial: 20692169
Drug: Anti-tuberculosis treatment
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis treatment (ATT)
Trial: 20692169
Drug: Current standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current standard therapies (Control)
Trial: 17464305
Drug: 360 degrees
RxNorm normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 360 degrees total capsule cover (group I)
Trial: 17464305
Drug: Quartile change
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quartile change in area of capsule cover
Trial: 15849647
Drug: Sports medicine
RxNorm normalized name: Mueller Sports Medicine Compression Glove
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sports medicine class
Trial: 15849647
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (students not participating in the sports medicine class)
Trial: 9708514
Drug: 1 mCi/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mCi/4 ml unfiltered 99mTc‐sulfur colloid injected in four divided doses around the palpable lesion or adjacent to the excision cavity
Trial: 26563923
Drug: Multimodal analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal analgesic (MMA) injection with morphine, ropivacaine, and methylprednisolone
Trial: 23510018
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to the highest approved dose of rosuvastatin (40 mg)
Trial: 23510018
Drug: Add-on extended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on extended release nicotinic acid (ER-NA)/l-aropiprant (LRPT)
Trial: 20706728
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil capsules (11 g/day)
Trial: 20706728
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil capsules (2 g/day + 9 g/day of olive oil)
Trial: 20706728
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil capsules (11 g/day)
Trial: 19936516
Drug: 10% Lippia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Lippia Sidoides (LS) gel
Trial: 25523604
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (control group)
Trial: 11299133
Drug: Sertraline 100mg
RxNorm normalized name: sertraline 100 MG
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline 100mg per day for 2 weeks
Trial: 9882034
Drug: Empirical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical treatment with omeprazole
Trial: 9882034
Drug: Prompt endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prompt endoscopy followed by directed medical treatment
Trial: 2803882
Drug: Bupivacaine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine with fentanyl (loading dose of 0.5% bupivacaine 6.0 ml and fentanyl 100 micrograms, followed by infusion of 0.08% bupivacaine 15 ml h‐1 plus fentanyl 37.5 micrograms h‐1)
Trial: 2803882
Drug: Bupivacaine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine alone (loading dose of 0.5% bupivacaine 6.0 ml and saline 2.0 ml, followed by infusion of 0.08% bupivacaine alone)
Trial: 4827462
Drug: 2.5 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg/70 kg heroin
Trial: 4827462
Drug: 5 mg/70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/70 kg heroin
Trial: 31620896
Drug: HPP/target therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPP/target therapy
Trial: 30839090
Drug: DWt +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWt + 400 mg/L of PLG
Trial: 30839090
Drug: DWt +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWt + 400 mg/L of LBS
Trial: 21346110
Drug: Oral Fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Fat Tolerance Test (OFTT: 1 g lipid/kg body weight) followed by caffeinated coffee (5 mg/kg)
Trial: 21346110
Drug: Caffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeinated coffee (5 mg/kg)
Trial: 19233423
Drug: Oxybutynin chloride
RxNorm normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin chloride topical gel (1 gm, 10% weight per weight, ethanol based formulation) once daily for 12 weeks
Trial: 16391591
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (glucomannan and plant sterols)
Trial: 1943932
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Monophosphothiamine (DB16023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin B1 and/or diuretics treatment for alcohol-related cardiomyopathy
Trial: 7005293
Drug: Flunisolide nasal
RxNorm normalized name: flunisolide nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunisolide nasal spray (300 micrograms/day or less)
Trial: 10520573
Drug: Testosterone patches
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone patches (5 mg testosterone over 24 hours)
Trial: 7669218
Drug: Fluoride-sucrose solution
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoride-sucrose solution (1 mg/kg, 5 mg/kg, 10 mg/kg)
Trial: 7030902
Drug: Heptavax B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavax B vaccine (40 micrograms each, three doses)
Trial: 7030902
Drug: Heptavax B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heptavax B vaccine
Trial: 29156875
Drug: Dexamethasone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.1 mg/kg IV 1 hour before anesthesia)
Trial: 26529601
Drug: 1.5 g
RxNorm normalized name: Vaporizer Vicks 1.5 gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 g of calcium HMB for 8 weeks
Trial: 15145964
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort (300 mg tablet, three times daily for 14 days)
Trial: 10430427
Drug: Ropinirole (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropinirole (0.75 mg, titrated to a maximum of 24 mg)
Trial: 10430427
Drug: Bromocriptine (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (1.25 mg, titrated to a maximum of 40 mg)
Trial: 1646621
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg) and felodipine ER (10 mg)
Trial: 1646621
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Ramipril and Felodipine)
Trial: 6950685
Drug: Cranial irradiation
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial irradiation plus 5 doses of i.t. MTX
Trial: 6950685
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of i.t. MTX after induction, repeated every 3 months
Trial: 6950685
Drug: BCG therapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG therapy by scarification
Trial: 29319497
Drug: Tigecycline plus
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline plus high-dose cefoperazone-sulbactam (1:1)
Trial: 25101831
Drug: Simvastatin (SIM)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (SIM) lipid-based formulation in gelatin capsules coated with Eudragit® S100
Trial: 25101831
Drug: Zocor® tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zocor® tablets (reference control)
Trial: 25101831
Drug: Simvastatin (SIM)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (SIM) lipid-based formulation
Trial: 24718367
Drug: Prasugrel 60-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 60-mg or 30-mg loading dose (LD)
Trial: 24718367
Drug: Clopidogrel 600-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 600-mg loading dose (LD)
Trial: 20598667
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group patients who crossed over to 0.5 mg ranibizumab
Trial: 20598667
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg ranibizumab after rollover to monthly dosing
Trial: 20598667
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg ranibizumab after rollover to monthly dosing
Trial: 12196219
Drug: One-visit treatment
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit treatment with gutta-percha and AH-26 sealer
Trial: 12196219
Drug: Two-visit treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-visit treatment with calcium hydroxide for 4 weeks followed by gutta-percha and AH-26 sealer
Trial: 9638715
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of mannitol
Trial: 9638715
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g of mannitol
Trial: 2574051
Drug: SK&F 101468
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK&F 101468 (doses between 80 micrograms and 2.5 mg)
Trial: 2574051
Drug: SK&F 101468
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SK&F 101468 (up to 1 mg)
Trial: 19149939
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (rhGH) 12 IU/d
Trial: 9177418
Drug: Carbimazole plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole plus low dose CT (Calsynar; 100 IU/day, 2 days/week)
Trial: 9177418
Drug: Carbimazole plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbimazole plus high dose CT (Calsynar; 100 IU/day, 14 days/month)
Trial: 8426767
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for upper respiratory infections
Trial: 3429867
Drug: AII/NA infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AII/NA infusion
Trial: 3429867
Drug: Dextrose/NA infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose/NA infusion
Trial: 3429867
Drug: All/saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All/saline infusion
Trial: 3429867
Drug: Dextrose/saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose/saline infusion
Trial: 17003850
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg exogenous melatonin orally
Trial: 17003850
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg exogenous melatonin orally + CYP2C19 substrate
Trial: 17003850
Drug: melatonin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melatonin treatment
Trial: 11277319
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 480 mg/day during RT
Trial: 9079231
Drug: NTG oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NTG oral spray (Myocor Spray)
Trial: 8421422
Drug: Three courses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of cis-platinum containing chemotherapy
Trial: 8421422
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of surgery and postoperative radiotherapy
Trial: 3784136
Drug: Topical forskolin
RxNorm normalized name: Coleus forskohlii root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical forskolin (50 microliter of 1% forskolin)
Trial: 3784136
Drug: Topical forskolin
RxNorm normalized name: Coleus forskohlii root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical forskolin (two instillations)
Trial: 3784136
Drug: Topical 0.25%
RxNorm normalized name: permethrin topical 0.25% topical kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.25% 1-timolol (pretreatment)
Trial: 30112725
Drug: DFN-11 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DFN-11 (3 mg sumatriptan injection)
Trial: 27502706
Drug: Consensus-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consensus-based treatment
Trial: 20156980
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual control (n = 15)
Trial: 18551027
Drug: Ramipril treatment
RxNorm normalized name: Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ramipril treatment group
Trial: 16334717
Drug: External application
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External application of Chinese drugs on acupoint Shenque (CV 8) combined with salpingostomy
Trial: 22424890
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events assessed using Young Mania Rating Scale (YMRS) and Systematic Assessment for Treatment Emergent effects (SAFTEE)
Trial: 20439846
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of mexiletine 3 times daily
Trial: 20439846
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of mexiletine 3 times daily
Trial: 6092982
Drug: LoNaHCO3 dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LoNaHCO3 dialysis (sodium bicarbonate, Na = 134, HCO3 = 33 mEq/l)